This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Gets European Nod for Aptima CMV Quant Assay
by Zacks Equity Research
Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Quest Diagnostics (DGX) Unveils Corporate Responsibility Report
by Zacks Equity Research
Per Quest Diagnostics' (DGX) 2020 Corporate Responsibility Report, it has expanded COVID-19 capacity throughout the year, performing 30 million COVID-19 molecular tests and serology tests.
Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters
by Zacks Equity Research
Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.
Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and bullish 2021 earnings guidance.
Abbott's (ABT) Base Business Recovers, Lowered View Concerns
by Zacks Equity Research
According to Abbott (ABT), significant reductions in the number of COVID-19 cases in the United States and other major developed countries to hamper demand for COVID-19 testing in 2021.
Thermo Fisher's (TMO) New Launch Boosts Preclinical Development
by Zacks Equity Research
Thermo Fisher's (TMO) enhanced Quick to Clinic solution provides balance of speed and quality to accelerate and advance DNA to Investigational New Drug in as less as 13 months.
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Phirbo (PAHC) Nutritional Specialties Grow, Vaccine Sales Dip
by Zacks Equity Research
Currently, Phirbo (PAHC) is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and bullish 2021 outlook.
Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta
by Zacks Equity Research
Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.
Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides
by Zacks Equity Research
The UroLift System remains a major contributor to Teleflex (TFX) revenues.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on its promising Surgical Structural Heart business and bullish 2021 guidance.
Henry Schein (HSIC) Enhances Dental Practices With New Deal
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of majority stake in eAssist will enable it to offer best quality solutions to help dental practices operate efficiently and profitably.
CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.
Thermo Fisher (TMO) End Markets Rebound as COVID-19 Cases Drop
by Zacks Equity Research
In academic and government end markets, Thermo Fisher (TMO) grows on robust customer activity globally.
Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod
by Zacks Equity Research
Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.
Here's Why You Should Retain CVS Health (CVS) in Your Portfolio
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.
STERIS (STE) Expands Product Suite With New Acquisition
by Zacks Equity Research
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Inogen (INGN) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 89.29% and 8.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
Inogen's (INGN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Inogen, Inc. (INGN).